Epstein–Barr virus (EBV) is an important pathogen in recipients of solid organ transplants
(SOT). Infection with EBV manifests as a spectrum of diseases/malignancies ranging from
asymptomatic viremia through infectious mononucleosis to posttransplant
lymphoproliferative disorder (PTLD). EBV disease and its associated PTLD is more
frequently seen when primary EBV infection occurs after transplant, a common scenario in
pediatric SOT recipients. Intensity of immunosuppressive therapies also influences the risk …